Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...
Flu is a viral infection affecting the nose, throat and lungs, mostly during the winter months. It is far worse than an ...
The transaction would allow Sanofi to solely focus on its more lucrative, drugs and vaccines business. The company's research-and-development spending increased 24% on-year in the last quarter in an ...